Oral tadalafil reduces intra-abdominal adhesion reformation in rats.
BACKGROUND
Currently, there is no ideal agent to prevent adhesion formation. We have shown that sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, reduces post-operative adhesion formation by vasodilatation and increases fibrinolytic activity. Here, we evaluated whether tadalafil, a long-acting PDE-5 inhibitor, decreases post-operative adhesion reformation in rats.


METHODS
Standardized lesions were created in Wistar albino rats by cauterization of uterine horns and abrasion of adjacent peritonium. The extent and severity of adhesions were scored on the 14th post-operative day and adhesiolysis was performed at the second laparotomy. Animals were then assigned randomly into two groups. The study group (n = 11) received 10 mg/kg oral tadalafil by gavage 60 min before the second laparotomy and daily for 14 days afterwards. Controls (n = 11) received the same volume of tap water for 14 days by gavage. Animals were killed 15 days after adhesiolysis and adhesions were scored blind during the third laparotomy. RESULTS Basal adhesion scores at the time of the second laparotomy were comparable in the study and control groups. Scores for the extent of adhesion reformation in the study and control groups did not differ [median 1 (range 0-3) versus median 2 (range 1-3); P: 0.81] but tadalafil reduced the respective severity scores [median 0.5 (range 0-1) versus median 1 (range 0.5-1); P: 0.02] and total scores [median 2 (range 0-4) versus median 2.5 (range 1.5-4); P: 0.042].


CONCLUSIONS
Oral administration of tadalafil during the perioperative period reduces intra-abdominal adhesion reformation in rats.
Department of Obstetrics and Gynecology, Faculty of Medicine, Erciyes University, Gevher Nesibe Hospital, 38039 Kayseri, Turkey. mskutuk@erciyes.edu.tr
Mehmet Serdar
MS
Kutuk
Mahmut Tuncay
MT
Ozgun
Cem
C
Batukan
Bulent
B
Ozcelik
Mustafa
M
Basbug
Ahmet
A
Ozturk
D000284:Administration, Oral; D000818:Animals; D002243:Carbolines / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D055502:Secondary Prevention; D000068581:Tadalafil; D000267:Tissue Adhesions / Q000188:drug therapy* / Q000601:surgery
D002243:Carbolines; D058986:Phosphodiesterase 5 Inhibitors; D000068581:Tadalafil